Health Condition 1: G30- Alzheimers disease Health Condition 2: F40-F48- Anxiety, dissociative, stress-related, somatoform and other nonpsychotic mental disorders Health Condition 3: N40- Benign prostatic hyperplasia Health Condition 4: J40-J47- Chronic lower respiratory diseases Health Condition 5: D50-D89- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism Health Condition 6: I00-I99- Diseases of the circulatory system Health Condition 7: K00-K9
Conditions
Interventions
Intervention1: Individualized Homoeopathy with usual care: Patients will be given individualized homoeopathy as per the homoeopathic principles for 12 months
Control Intervention1: Placebo with usual
Sponsors
Central Council for Research in Homoeopathy
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients suffering from two or more of the chronic conditions 2. Patients who are under usual care for the suffered chronic conditions. 3. Ability to comply with the study protocol 4. Voluntary written Informed consent
Exclusion criteria
Exclusion criteria: 1. Patients suffering from only one of the clinical conditions. 2. Inability to comply with the study protocol. 3. Severe mental health problems: schizophrenia, bipolar affective disorder, or other psychotic illnesses. 4. Life-threatening illnesses, malignant tumours, HIV etc. 5. Patients, at the time of enrolment, should not be suffering from any acute clinical condition that has no association with their chronic ailment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be the health-related quality of life (HRQoL) as measured by the EQ-5D-5L utility scoreTimepoint: Baseline, Month 12 | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate changes in HRQOL using EQ-5D-5L, PROMIS 29, BIPQ, MULTIPLEs questionnaires at different time points. Incidences of hospital admissions among the two groups. Reduction of usual care drugs, differences in the cost of medical expenditure, changes in laboratory parameters among the two groups. Occurrence of adverse events.Timepoint: Baseline, and over 12 months | — |
Countries
India
Contacts
Public ContactDr Debadatta Nayak
Central Council for Research in Homoeopathy, New Delhi
Outcome results
None listed